Advances in the optimization of therapeutic drug monitoring using serum, tissue and faecal anti-tumour necrosis factor concentration in patients with inflammatory bowel disease treated with TNF-α antagonists.
Kata Judit SzántóTamara MadácsyDiána KataTamás FerenciMariann RutkaAnita BálintRenáta BorAnna FábiánÁgnes CsontosBoldizsár JójártZoltán SzepesFerenc NagyTamás MolnárImre FöldesiJózsef MaléthKlaudia FarkasPublished in: Expert opinion on biological therapy (2021)
Fecal drug concentration is suggested to be a better predictor of endoscopic activity and loss of response, and fecal drug monitoring may improve the estimation accuracy of tissue drug levels.